{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:02:21Z","timestamp":1753358541306},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.lungcan.2003.10.005","type":"journal-article","created":{"date-parts":[[2003,12,19]],"date-time":"2003-12-19T05:58:32Z","timestamp":1071813512000},"page":"111-119","source":"Crossref","is-referenced-by-count":5,"title":["A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies"],"prefix":"10.1016","volume":"44","author":[{"given":"Afshin","family":"Forouzannia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Boothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Storer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2003.10.005_BIB1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","article-title":"The current status of camptothecin analogues as antitumor agents","volume":"85","author":"Slichenmeyer","year":"1993","journal-title":"J. Nat. Cancer Inst."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0027-5107(88)90201-1","article-title":"Anticarcinogenic potential of DNA repair inhibitors","volume":"202","author":"Boothman","year":"1989","journal-title":"Mutat. Res."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB3","first-page":"5361","article-title":"Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by B-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor","volume":"47","author":"Boothman","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB4","first-page":"605","article-title":"Inhibition of potentially lethal DNA damage repair in human tumor cells by B-lapachone, an activator or topoisomerase I","volume":"49","author":"Boothman","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0360-3016(92)90478-Z","article-title":"Post-treatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells","volume":"24","author":"Boothman","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0360-3016(92)90865-F","article-title":"Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I","volume":"22","author":"Kim","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB7","first-page":"5813","article-title":"Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)","volume":"51","author":"Mattern","year":"1991","journal-title":"Cancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2003.10.005_BIB8","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.2307\/3578778","article-title":"Enhanced malignant transformation is accompanied by increased survival recovery following ionizing radiation in Chinese hamster embryo fibroblasts","volume":"138","author":"Boothman","year":"1994","journal-title":"Radiat. Res."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB9","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1073\/pnas.86.13.4963","article-title":"Inhibition of radiation-induced neoplastic transformation by B-lapachone","volume":"86","author":"Boothman","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB10","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.1996.14.8.2345","article-title":"Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial","volume":"14","author":"Schiller","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1067\/mcp.2002.123553","article-title":"Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors","volume":"71","author":"Mould","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB12","unstructured":"Topotecan investigator\u2019s brochure. SmithKline Beecham, 1994."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB13","doi-asserted-by":"crossref","unstructured":"Burris HA 3rd, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, et-al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84:1816\u201320.","DOI":"10.1093\/jnci\/84.23.1816"},{"key":"10.1016\/j.lungcan.2003.10.005_BIB14","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1200\/JCO.1997.15.5.2090","article-title":"Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group","volume":"15","author":"Ardizzoni","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB15","first-page":"1816","article-title":"A multicentre randomized phase II study of oral topotecan versus i.v. topotecan for second line therapy in sensitive patients with small-cell lung cancer","volume":"18","author":"Von Pawel","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB16","first-page":"1087","article-title":"New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: a review of the literature and future directions","volume":"5","author":"Bunn","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1006390216220","article-title":"A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339)","volume":"18","author":"Macdonald","year":"2000","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2003.10.005_BIB18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/neuonc\/5.1.8","article-title":"A phase I study of topotecan, as a radiosensitizer for brainstem glioma of childhood: first report of the Children\u2019s Cancer Group-0952","volume":"5","author":"Sanghavi","year":"2003","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.lungcan.2003.10.005_BIB19","first-page":"868","article-title":"Phase II study of oral topotecan in advanced non-small-cell lung cancer","volume":"6","author":"White","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.2001.19.6.1743","article-title":"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer","volume":"19","author":"Von Pawel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.10.005_BIB21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0959-8049(01)00188-5","article-title":"A randomized trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer","volume":"38","author":"Gore","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2003.10.005_BIB22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500203005373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500203005373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T21:51:54Z","timestamp":1550267514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500203005373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0169500203005373"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2003.10.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}